Global. Trilogy International Limited revenue increase by 4% to US$49.7 Mln in the first half of the 2018 financial year

TRILOGY INTERNATIONAL LIMITED; Trilogy International Limited Announces 1H FY18 results 28 de noviembre de 2017 ASX ComNews (Text version of ASX Company Announcements) (Australia) Trilogy International Announces First Half FY18 Financial Results Revenue to $49.7 million EBITDA of $6.3 million 28 November 2017 – Trilogy International Limited (NZX:TIL, ASX:TIL) (the company or TIL), the cultivator of essential natural skincare and home fragrance brands and distribution company, today announced first half FY18 financial results for the six months ended 30 September 2017. Angela Buglass, Chief Executive Officer of TIL, said, “TIL delivered modest growth in the first half, despite retail market pressure in its home markets of Australia and New Zealand. We delivered on our strategy to grow international markets, which grew over 200% compared to last year. Lanocorp has made a great start and as expected, is quickly proving to be a complementary skincare brand for the group. Cost impacts and short term quality issues impacted TIL group profitability, however, we have already implemented initiatives to accelerate growth in the second half, keeping us on track with previously disclosed guidance.” First Half ’18 Financial Highlights:  Revenue increased by 4% to $49.7 million  EBITDA declined by ($0.9m) to $6.3 million  NPAT increased 17% to $4.1 million  Natural Products delivered $18.7 million revenue, an increase of 4.8%  Home Fragrance & Bodycare delivered $8.3 million revenue, a decrease of (7.3%)  Full three months’ contribution from Lanocorp delivered $3.1 million revenue and EBITDA of $0.7 million. Revenue Maintained at 4% growth HoH Natural Skincare delivered 4.8% revenue growth, to $18.7 million, mainly driven by international market growth, which grew at 235% HoH. During the half we saw the formalisation of a more structured distribution channel in China CBEC. Trilogy Skincare maintained #1 market share position in New Zealand pharmacy1 and #2 in Australian pharmacy2 despite the compressed retail market, delivered 11 new products to market, and agreed ...